ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

DWP712

A development code. Also written as “DWP712 inj.”.

Its studies are led by Daewoong Pharmaceutical.

Furthest: phase 3, since Jun 2, 20252 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Daewoong Pharmaceutical21 open or runningphase 3since Jun 2, 2025Jan 8, 2024none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 8, 2024First study: phase 1 study in Glabellar LinesFirst studyNCT06212960 · 20 enrolled · Korea, Republic of
  2. Jun 2, 2025Phase 3 study in Glabellar LinesNCT07013279 · 324 planned · Korea, Republic of

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07013279Glabellar Lines · Korea, Republic of3Not yet recruitingDec 31, 2025324
NCT06212960Glabellar Lines · Korea, Republic of1CompletedFeb 26, 202420

How it is read

Names in the registry

  • “DWP712 inj.”, 1 entry
  • “DWP712”, 1 entry

Codes read as this program: DWP712.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.